Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and ...

Retrieved on: 2021-12-06 15:05:13

Tags for this article:

Clinical medicine

Cancer immunotherapy

Medicine

Life Sciences

Tumor microenvironment

Biotechnology

Monoclonal antibodies

Antineoplastic drugs

Virotherapy

Sotio

Bolt Biotherapeutics, Inc.

Trastuzumab

Click the tags to see associated articles and topics

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and .... View article details on HISWAI: https://www.biospace.com/article/releases/bolt-biotherapeutics-reports-interim-bdc-1001-phase-1-2-data-demonstrating-a-safe-and-well-tolerated-profile-and-emerging-clinical-activity-at-the-esmo-immuno-oncology-congress-2021-/

Excerpt

... and adaptive immune systems, today announced the presentation of interim clinical data from the company's ongoing Phase 1/2 study of BDC-1001, ...

Article found on: www.biospace.com

View Original Article